Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051659 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT03051659 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 90 participants.
The verdict
NCT03051659, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2023-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03051659
The ClinicalTrials.gov registry entry for NCT03051659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03051659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03051659 about?
NCT03051659 is a clinical study titled "A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer". This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.
What is the current status of trial NCT03051659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2017-03-22. Estimated completion is 2023-09-05.
What interventions are being tested in trial NCT03051659?
The interventions under investigation include: Pembrolizumab (DRUG), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT03051659?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.